Sipuleucel-T in metastatic castration-resistant prostate cancer

BioDrugs

Volumn 25, Issue 4, 2011, Pages 255-256

  Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Profile Reports; Cancer vaccines; Prostate cancer; Sipuleucel T

Indexed keywords

ANDROGEN; CANCER VACCINE; DOCETAXEL; PLACEBO; PROVENGE;

ANDROGEN DEPRIVATION THERAPY; ARTHRALGIA; ARTICLE; BACKACHE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CASTRATION RESISTANT PROSTATE CANCER; CHILL; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; FATIGUE; HUMAN; LEUKAPHERESIS; LYMPH NODE METASTASIS; METASTASIS; NAUSEA; PATIENT MONITORING; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SURVIVAL RATE; TREATMENT OUTCOME;

CANCER VACCINES; HUMANS; LYMPHOCYTE ACTIVATION; MALE; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; T-LYMPHOCYTES; TISSUE EXTRACTS;

EID: 80051535536     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11207140-000000000-00000     Document Type: Article

References (16)

1. AmericanCancer Society. Prostate cancer:what are the key statistics about prostate cancer? [online]. Available from URL: http://www.cancer.org/Cancer/ Prostate Cancer/DetailedGuide/prostate-cancer-key-statistics [Accessed 2010 Oct 12]
2. Jemal A, Sigel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225-49
3. American Cancer Society. Prostate cancer: what are the risk factors for prostate cancer? [online]. Available from URL: http://www.cancer.org/Cancer/ Prostate Cancer/DetailedGuide/prostate-cancer-risk-factors [Accessed 2010 Oct 12]
4. American Cancer Society. Prostate cancer: 5-year relative survival rates by stage [online]. Available from URL: http://www.cancer.org/Cancer/Prostate Cancer/DetailedGuide/prostate-cancer-survival-rates [Accessed 2010 Oct 12]
5. Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice: localized prostate cancer. N Engl J Med 2007 Dec 27; 357 (26): 2696-705
6. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007 Dec; 178 (6): 2359-64
7. American Cancer Society. Prostate cancer: initial treatment of prostate cancer by stage [online]. Available from URL: http://www.cancer.org/Cancer/ Prostate Cancer/DetailedGuide/prostate-cancer-treating-by-stage [Accessed 2010 Oct 12]
8. Di LorenzoG, Buonerba C, Autorino R, et al.Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010 May 28; 70 (8): 983-1000
9. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010 Aug; 10 (8): 580-93
10. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 Oct 7; 351 (15): 1513-20
11. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 Oct 7; 351 (15): 1502-12
12. Sheikh NA, Jones LA. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother 2008 Sep; 57 (9): 1381-90
13. Sipuleucel-T (Provenge): US prescribing information. Seattle (WA): Dendreon Corporation, 2010
14. Plosker GL. Sipuleucel-T in metastatic castration-resistant prostate cancer. Drugs 2011; 71 (1): 101-8
15. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363 (5): 411-22
16. Hall SJ, Schellhammer PF, Higano CS, et al. Integrated safety results from four randomized, double-blind, placebo-controlled studies of sipuleucel-T [abstract no. 674]. J Urol 2010 May 31; 183 (4): e263